Diabetic subjects have been shownt oh avea ltered fibrin network structures.One proposedmechanism forthis is non-enzymaticglycation of fibrinogendue to highbloodglucose.We investigatedwhether glycaemic control would result in altered fibrin networkstructures duetodecreasedfibrinogen glycation. Tw enty uncontrolledtype 2diabetic subjects were treatedwith insulin in ordert oa chieve glycaemic control. Tw enty age-a nd bodymass index(BMI)-matched non-diabetic subjects were included as ar eference group.Purified fibrinogen, isolated from plasma sampleswas usedfor analysis.Therewas asignificant decrease in fibrinogen glycation (6.81 to 5.02mol glucose/mol fibrinogen) with acorresponding decrease in rate of lateralaggregation (5.86 to 4.62) and increasedpermeability(2.45 to 2.85 x 10 -8 cm 2 )a nd lysisr ate (3.08 to 3.27 µm/min) in the diabetic subjects afterglycaemic control.Thesevariablescorrelated with Keywords Diabetes,fibrin network,fibrinogen glycation,glycaemic control, hyperglycaemia markerso fg lycaemic control. Fibrin clots of non-diabetic subjects had as ignificantly higherr atio of inelastic to elastic deformation than thed iabetic subjects (0.10 vs.0.09).Although there was no difference in median fiber diameterbetween diabetic and non-diabetic subjects,there was asmallincrease in the proportion of thicker fibers in the diabetic samplesa fter glycaemic control.Results from SDS-PAGEindicated no detectable difference in factor XIIIa-crosslinking of fibrin clotsbetween uncontrolled and controlled diabetic samples. Diabetic subjects mayhavealtered fibrin networkf ormation kineticswhich contributes to decreasedp ores ize and lysisr ate of fibrinc lots. Achievement of glycaemiccontroland decreasedfibrinogen glycation levelimprovespermeabilityand lysisratesinapurified fibrinogen model.
Introduction
Diabetes is apowerfuland independent risk factor forcardiovascular disease, with atherosclerosis amongthe most serious complications of type 2d iabetes ( 1) . Since fibrin is deposited at atherosclerotic lesions, the structureofthe deposited fibrin network has comeunder investigation as apossible contributing risk factor forincreased prevalenceofatherosclerosis-related cardiovascularevents. Fibrin networks canvaryinstructurefrom tight networks formedwith thin, highly branchedfibers, to looser networks made up of larger fibers. It has beend emonstrated that myocardialinfarction at ayoung age is indeedassociatedwith a proneness to the formation of tight and rigidfibrin gelstructures (2, 3) . Fibrin clots with thinner fibers, more branch points and smaller intrinsicporesare in general moredenseand resistant to lysis, thereby contributing to thrombotic risk (4) .
Forthis reason, fibrin networks of diabetic patients have receivedc onsiderablea ttention as ap ossible contributor to in-creased cardiovasculardiseaserisk. Oneofthe most important plausible mechanisms for alterations to fibrin networks of diabetic patients is the non-enzymatic glycation of fibrinogen in the presenceo fu ncontrolled blood glucose levels, whichm ay influence the functionality of the fibrinogen. Researchershaveinvestigated this issue by using either in vitro glycated fibrinogen (5) (6) (7) (8) (9) or collecting samples from diabetic subjects containing in vivo glycated fibrinogen (10) (11) (12) (13) (14) .When using diabetic samples, af urther distinction wasm ade in the use of eitherp lasma (11) (12) (13) (14) or purified fibrinogen models (10, 12, 15) Apart from the differingapproachesused, avastarray of variableswas also measured,i ncluding both structural and functional characteristics, in ordertogainabetterunderstanding of the effects of diabetesonfibrin networks.
Interpreting results from studiesw herefibrinogenw as glycated in vitro should be donewith caution, as there is asignificant difference between fibrinogen glycation in vitro and in vivo, making extrapolation to in vivo situations difficult. While using samplesf rom diabetic patients mayb em ore physiological,i t should be kept in mind that the diabetic state has manyo ther components thatc ould potentiallyi nfluence fibrin network structure, apart from fibrinogen glycation, such as increased lipidlevels (16) , increased fibrinogen concentration (17, 18) and glycation of other plasma proteins. In general, clots formed from diabetic patients were found to be denser, withthinner fibersand were less porous thanthose formed from healthyindividuals (10, 11, 16) . Pieters et al. (14) found,however,nodifference in network characteristicsofdiabetic patients compared to healthyindividuals, despite as ignificant difference in the levelo ffibrinogenglycation, when using plasma samples. In this studypopulation, however, both the diabetic and healthyi ndividuals had similar and raised fibrinogen levels. Thef ibrin networkc haracteristics also correlated with baseline fibrinogen concentration butn ot with anyo ft he markers of glycaemic control. Similar correlation patternsw ere observed by Jörneskog et al. (16) indicating the importanceofplasma constituents otherthan fibrinogen glycation on fibrin network structure.
The ideala pproach to examine the roleo ffibrinogeng lycation on fibrin network structures of diabetic patients would be to conductanintervention trial specificallydesignedtoinvestigate the effect of glycaemic control on fibrin network structures. Most of the above mentioned studiesondiabetic subjects, however,w ere cross-sectionalb ydesign, making the establishment of causal relationships impossible.Todate, only twointervention studies have beenperformed on this topic,one investigating type 1diabetic patients (16) and the other investigating type 2diabetic subjects, performed by our group (14) .The scarcity of studies such as these is not surprising since theyrequirethe unique combination of an intervention trial with patients and difficulta nd time-consuming structural and biophysicals tudieso fc lot networks.T wo papers have beenpublished from the study done by our group. The first describes the effect of glycaemic control on fibrinogen glycation and the association betweenfibrinogenglycation, fasting glucose and HbA1c ( 19) . The second describes the effect of glycaemic control on fibrin network structureusing plasma samples in ordertoinclude the possible contribution of individual fibrinogen concentrations on the fibrin networks (14) . In ordertodetermine the specificeffectsoffibrinogenglycation on fibrin network structures in the absence of other possibly confounding plasma proteins, we excluded the effectsofotherplasma components for the purposeofthis paper, by purifying fibrinogen from the collected plasma samples, therebyestablishing a purified fibrinogen model. The discussion will include interpretation of the resultsobtained from both plasma and purified fibrinogen models in ordertodemonstrate howresults maybeinfluencedbythe model used.
Materials andmethods

Study design
Am inimum of 16 volunteers had to be includedp er group in ordert oa chievead ifference of ones tandard deviation at 80% powera nd 5% levelo fs ignificance. To accommodate possible non-compliers and drop-outs, 20 volunteers were recruitedper group. Ap arallel, controlledi ntervention with blindeda ssessmentw as used. Twentyb lack African type 2d iabetic subjects, uncontrolled on oral hypoglycaemic agents, were includedand treateda dditionallyw ith insulin until glycaemic control was achieved (4 outof5subsequent readings within normal glucose range).F ollowing this initial period of improving and finally achieving glycaemic control, the patients then had to remain controlled for eight days before end blood samples were drawn. This eightday period waschosen in ordertoprovide enoughtime for unglycated fibrinogen to be produced (half-life 3-4 days) after glycaemic control had beenachieved. Twentynon-diabetic black African subjectsw ere includeda sar eference group in ordertocontrol for variation over time.All subjectssignedinformed consent and ethicala pprovalw as obtainedf ormt he ethics committeeso fb oth the University of Pretoria and the North-West University,South Africa.
Subjects
Ty pe 2diabetic subjects Inclusionc riteria: patients hadt ob eu ncontrolled (HbA1C > 9%) on maximum dose combination oralhypoglycaemic medication (Metformin and Sulphonylureas);body mass index(BMI) >25kg/m 2 ;40-65 years of age with blood pressure sufficiently controlled(<140/90 mmHg) not to necessitate treatment change during intervention (hidrochlorothiazide,ACE-inhibitor -Perindopril and Calcium antagonist -Nifedipine).
Exclusionc riteria: major surgery in the preceding six months; macrovascularc omplications;d iseases thatm ay influence haemostasis (e.g.t hrombocytopenia, cancer, liverd isease); patients on aspirin, warfarin,steroids,hormone replacement therapyornon-steroidal anti-inflammatorydrugs; proteinuria on urine dipstick (> 300 mg/day) or acute infection.
Non-diabetic controls
Non-diabetic subjects withm atching anti-hypertensive druguse, age,gender and BMI were recruited. Thesameinclusion and exclusion criteriaasfor the type 2diabetic subjectswere adhered to. Baseline oral glucose tolerance tests were done to rule out diabetes.
Study protocol
The intervention in the diabetic group consisted of threephases.
Phase 1
On thefirst visit, diabetic subjectsw ere taughthow to do selfglucose monitoring,c o-ordination of insulin use with meals, symptoms and management of hypoglycaemic eventsa nd the use of glucagon. Fasting capillary glucose wasm easured daily for oneweek.
Phase 2
Subjectsreceived10IUbasal analogue insulin Glargine (Lantus, Sanofi-Aventis Pharmaceuticals, Paris, France) daily at 10 p.m. in addition to currenttreatment of maximum doseoral hypoglycaemic treatment. Metformin use wasu nchanged from before and during the intervention. Insulin administration wasadjusted individuallyuntil four out of five subsequent fasting valueswere less than7.2 mM. Sulphonylureas were stopped.
Phase 3
Post-prandialglucose wasnow controlledwith pre-meal administration of short-acting insulin Aspart (Novo Nordisk,B agsvaerd,D enmark)a sr equired to achievep ost-prandial glucose valuesoflessthan 10 mM. Onceboth fasting and post-prandial glycaemic control wasachieved,the subjects remained on treatment for eight days. Baseline blood samples and anthropometric measurements were collected at the end of phase1a nd end samples and measurements at the end of phase 3. Blood samples of non-diabetic subjects were drawn within one week of blood sampling from their matcheddiabetic subjects.
Bloodsampling
Fasting venous blood samples were drawn with minimalstasis by ap hysicianb efore 10 a.m.B lood for venous glucose determination, wascollectedinto sodium fluoride tubes. EDTAblood wascollectedfor the determination of HbA1C. Citrate blood (60 ml) wasc ollectedf or the determination of fibrinogen concentration, fibrinogen glycation and for fibrinogen purification. Blood wasc entrifuged for1 5m inutes( min) at 2,000ga t4°C within3 0m in of collection. Serum and plasma were stored at -82°Cuntil analysis. Baseline and end samples of an individual were analyzed in the same runf or all experiments. Scanning electron microscopy( SEM),a nd viscoelastic measurements were performed in adifferent laboratorythan the other analyses.
Glucoseand HbA1C
Plasmaglucose and baseline HbA1Cw ere measured on aSynchron LX clinicalSystem (Beckman Coulter Inc., Fullerton, CA, USA).
Fibrinogenconcentration, purification and glycation
Plasmafibrinogen(modifiedClauss method)was measured on an AutomatedC oagulation Laboratory2 00 (Instrumentation Laboratories, Milan, Italy)(between-run CV =3%). Fibrinogen wasp urified from the plasma of each subjectu sing IF-1(fibrinogen monoclonal antibody,K amiya Biomedical Company, Seattle,W A, USA) affinity chromatographya sd escribed previously ( 20) . Purified fibrinogen wasr un on 10% SDS PAGE gels to confirmpurity and the absence of degradation of the fibrinogen preparations. No bands, apart from the three intact fibrinogen chains were present on the gels. Thebroad-rangemolecular-weight standard used ranged from 35 to 250 kD.F ibrinogenglycation wasmeasured in duplicate, with atwo-reagent enzymatica ssay( GlyPro ® assay, Genzyme Diagnostics, Cambridge, MA, USA; between-runC V=5%) as describedp reviously (14) .
Clotpermeability
Permeability wasm easured essentiallya sd escribed previously (11,2 1). Purified fibrinogen (1 mg/ml) clots of subjects were prepared in triplicatein3cm sections of 1mlpipette tips. Fibrinogen wasclottedwith the addition of 1U/ml bovine thrombin, 5mMCaCl 2 and incubatedfor 60 min at 25°C in amoist atmosphere. Bufferwas permeated throughatapressure heightof6cm (CV=7%).These conditions were selected in ordertoprevent clots from collapsing. Permeability (Ks), an indication of the intrinsic poresizeofthe network, wasthen calculated (22) .
Tu rbidity measurements
Turbidity experiments were performed in duplicatewith purified fibrinogen (1 mg/ml), 1U/ml bovine thrombin and 5mMCaCl 2 (finalc oncentrations). Absorbance wasm easured at 405n m every7seconds (s)for the first 2min after addition of thrombin and CaCl 2 ,then every15sfor the next 30 min and then every 5min up to atotal timeof60min on aMultiscanAscent spectrophotometer( Labsystems, Helsinki, Finland).L ag phase, slope and maximum absorbance were recorded.The lag phase represents the timerequired forfibrin fiberstogrowsufficiently to allowlateral aggregation and wastaken at the pointwhereabsorbance increased 0.015 from baseline. The slope, calculatedat half maximum absorbance, represents the rate of increase of turbidity, and the maximum absorbance, calculated as the absorbance after 60 min minus thatatbaseline,isanindication of average fiber size.
In ordertodetermine whether fibrinogen glycation is one of the mechanisms of action through whichfibrin networkarchitecturei sa ltered in diabetes, the experiments mentioned below were performed on subjectswith striking differences in the degree of fibrinogen glycation. Due to the difficulty and time consuming nature of the experiments, asubset of 12 subjects consisting of sevend iabetic subjectsw ho showedt he largest decrease in fibrinogen glycation from baseline to end and five randomlyselected non-diabetic subjectsw ere investigated forthis purpose.
SEM of fibrin clots andfiber diametermeasurement
SEMwas used to determine the fibrin structureofclots formed from purified fibrinogen of diabetic and control subjects. Clots were formedb ya ddition of 0.5 U/ml α-humant hrombin and 3mMCaCl 2 to 1mg/ml fibrinogen in 0.15 MNaCl, 0.05MTris-HCl, pH 7.4.S amples were prepared as described previously (23) . Clotsw ere observed and photographed digitallyi nm any differenta reas, using as canning electronm icroscope( XL 20, FEI, Hillsboro, OR,USA). Fiber diameters were measured from micrographsa t1 0,000 xm agnification usingI mageJs oftware (National Institutes of Health, USA). The thicknessesofatleast 100different fiberswere measured per micrograph,with at least six micrographsimagedfor each patient.
Viscoelastic measurements of fibrin clots
APlazek torsion pendulum wasusedtodetermine visco-elastic propertieso fc lots, includingc lot stiffness ( 24) , in triplicate, formed from purified fibrinogen from diabetic subjects and controls under the same conditions as describeda bove.D atar ecorded wasusedtocalculateG'(the dynamic storage modulus), G" (the loss modulus) and the tanδ (losst angent), whichi sa function of G" over G' and givesinformation about irreversible deformation of the clot (24) .
Lysis rateoffibrin clots measured by confocal microscopy Fluoresceini sothiocyanate (FITC) (Pierce, Rockford,I L, USA) labeledfibrin clots were preparedu sing 1m g/mlp urified fibrinogen, 0.15 mg/ml FITC-labeled fibrinogen, 1U /ml bovine thrombin and 5mMCaCl 2 .The fibrinogenwas labeled with FITC as described by Sakharovetal. (25) .The clots were preparedin micro-chambers and incubatedfor 45 minat37°C in amoistatmosphere before being lysed withalysisbuffercontaining 1 µg/ ml tissueplasminogen activator (tPA) (Actilyse from Boehringer Ingelheim, Ingelheim, Germany),1mg/mlbovine serum albumin (BSA) (Sigma-Aldrich, St Louis,U SA), 210 µg/mlh umang luplasminogen (American Diagnostica, Stamford,C T, USA),1 40 mM NaCland 50 mM Tris,pH7.4. After a15min incubation at 37°C in amoistatmosphere, lysisrate wasmeasured by following the lysisf ront on aP CM 2000 Nikonc onfocal laser scanning microscope linked to aN ikon TE300 inverted microscope equippedwith an ApoPlanar1.4NA60xoil immersion objective. A5 -W argon ion laser wasu sed in combination with a4 88 nm band-pass filter forexcitation. Emission wasmonitoredat505 nm. Apinhole of 5micron and a10% neutral densityfilter were used to limitbleaching of the FITC-label. Images were obtained using astandardizedformat: 107 x107 x16µmwith four opticalsections collected at z-intervals of 4 µm. Lysisfront velocity wasdeterminedatthreedifferent sites along the lysisfront in triplicate, in ordertocalculatethe mean lysisrate in µm/min.
Analysis of fibrin cross-linkingb ySDS-PAGE
InitialS DS-PAGEr esults indicated thatt he fibrin clots made from the purified fibrinogen contained very little if anyf actor (F)XIII. In order to determine whether fibrinogen glycation has an effect on FXIIIac rosslinking, we performed SDS-PAGE analysis with and withoutadded human FXIII (AmericanDiagnostica) using an incubation time series. FXIII (22 µg/ml) was added to the purifiedfibrinogen(1mg/ml) and clots were formed by the addition of 1U/ml bovine thrombin and 5mMCaCl 2 (finalconcentrations)at21°C in 20 µlreaction mixtures which were thenincubated for 10, 45 or 90 min. Control samples without addedFXIII were incubatedfor 90 min, in ordertodemonstrate the absence of FXIII in the purifiedfibrinogen. Theligating reaction wasstopped by solubilization in 6Murea, 40 mM dithiothreitol and 2% (w/v) SDSat37°C for 45 min. Gelelectrophoresis [8% (w/v) acrylamide] wasperformed by the procedure of Laemmli (26) . Samplesof6µgprotein per lane were analyzed and abroad-rangemolecular weight standard (Amersham) was used as ar eference. Coomassieb rilliant blue R( Biorad,H ercules,C A, USA) wasu sedf or staining. The gel wasp hotographed on aS ynGene bio-imaging system and peaks were identifiedand quantified using GeneTools softwareversion 3.06 (SynGene, Cambridge, UK ).
Statisticalmethods
The computer softwarepackage, Statistica(StatsoftInc., Tulsa, OK,USA)was used forstatistical analysis. Data is presented as median [25 th ;75 th percentile].Differences in baseline characteristicsa sw ella sd ifferences in changes during the intervention between the twogroups were determinedusing the Mann-WhitneyUtest. Differences from baseline to end within each group were determinedusing the Wilcoxon Matched Pairstest. Once statistical significanceh as been indicated,e ffect sizesc an be used to determine whether this significance is likelytobeimportant in practice. Theeffect size is independent of sample size and is an objectivemeasureofthe likelihood of adifference having a practical/clinical significance. Effect sizesw ere calculated according to the followingformula: r=z/√nfor non-parametric data (z is the z-statistic obtained from the non parametric test and nis the number of observations). Thelikelihoodofthe found statistical significance being practically relevant, is reported as effect size (r)and canbeinterpreted as follows; r=0.1 is asmall likelihood, r=0.3 is amedium likelihoodand r=0.5 is alarge likelihood for non-parametricdata (27) . Spearman-correlation wasusedfor determining correlation coefficients.
Results
Twoo ft he non-diabetic subjects failedt or eturnf or end blood sampling and were hence excluded fromthe study.Asummaryof the most relevant baseline characteristics arepresentedinTable 1w hile the detailed baseline characteristics of the study population have beenpresentedindetailelsewhere (14) . 
Variables
Ty pe 2diabetic subjects N on-diabeticsubjects 
Fibrinogenglycation
There wasasignificant decreaseinthe leveloffibrinogenglycation uponachievement of glycaemic control (6.81 vs.5.02 mol glucose/mol fibrinogen) ( Table 2) as well as as ignificantly higher leveloffibrinogenglycation in the diabetic compared to the non-diabetic subjects(6.81 vs. 3.84 mol glucose/mol fibrinogen) at baseline. Forthe sub-sample, selectedbased on the largest decrease of fibrinogen glycation during the intervention, the levelofglycation decreased from10.7 to 5.07 mol glucose/mol fibrinogen. Effect size calculations indicatedt hat these differences are largeenough to not onlyhavestatistical significance butalso have possible practicalrelevance.
Clotpermeability
Clot permeability reflectst he clot structure, specificallyt he averagep ore size.T he resultsi ndicated both as tatistically as well as alarge likelihoodofapracticallyrelevant increase in permeability from baseline to end in the total diabetic group (2.45 to 2.85x10 -8 cm 2 ). This relatively small butconsistent increase was also observed in the sub-sample(2.24 to 2.84x10 -8 cm 2 )( Table  2 ). There wasnochange in permeability in the non-diabetic subjects, nor wasthereany difference betweenthe diabetic and nondiabetic subjects at baseline. There wasadditionallyasignificant correlation between permeability and HbA1ca tb aseline (r=-0.63;p=0.038).
Tu rbidity measurements
Turbidity curvesare used to characterize the kineticsofpolymerization and clot structure. No difference in the lag time(time for fibrinopeptide cleavage and formation of oligomers) or maximum absorbance (average cross-sectional area of fibers) wasobservedbetween the uncontrolleddiabetic,controlled diabetic or the non-diabetic subjects ( Table 2 ). The slope of increase in turbidity(rate of lateral aggregation) for the diabetic subjectswas, however, significantlyhigherthan that of the non-diabetic subjects at baseline, both for the total group (5.86 vs. 
Fiber diameter
Clot structurewas observed directly by SEM. The median fiber diameterofthe clots from diabetic and non-diabetic subjects was similar (Table 2and Fig. 1 ) at baseline and no significant change in the medianfiberdiameterwas observed after achieving glycaemic control (Table 2) .Therewas,however,asmall increase in the proportion of thickerfibers in the clotsofthe diabetic subjects after glycaemic control as measuredfrom the SEM micrographs, indicating alesshomogeneous clot structure (Fig. 2) .
Viscoelastic properties
The mechanical properties of the clots arei mportant for their functions. There wasnosignificant difference in dynamic storage modulus (elastic properties) or loss modulus (viscous properties) between the uncontrolleddiabetic,controlled diabetic or the non-diabetic subjects ( Table 2 ). The resultsshowed, however as tatistically significant differencei nt he loss tangent (tanδ) measurement (ratio of inelastic to elasticc omponent) between the diabetic and non-diabetic subjects (0.09 vs. 0.10) at baseline, reflecting alower proportion of the inelastic componentinthe fibrin clots of diabetic patients.
Lysis rate
Fibrinolysis rates were determinedbymeasurement of the lysis front velocity usingconfocal microscopyafter addition of tPAto the edge of aclot (Fig. 3 ).The diabetic subjects had alower lysis rate thanthe non-diabetic subjects (3.08 vs. 8.52 µm/min). While the statisticals ignificance wasb orderline (p=0.06), the likelihood of apractical relevance wasconsideredtobelarge (r=0.54) ( Table 2 ).Asignificant increaseinlysis rate wasobservedwith achievement of glycaemic control in the diabetic subjects(3.08 to 3.27 µm/min). Although this increase wassmall in comparison to the difference between the diabetic and non-diabetic subjects, it wasseen consistentlyineach diabetic subject measured. Lysis rate showedsignificant negative correlations with the level of fibrinogen glycation (r=-0.63, p=0.028), HbA1c (r=-0.64, p=0.026), fasting venous glucose (r=-0.60, p=0.039) and slope (r=-0.77, p=0.009).
Effect of fibrinogenglycation on FXIIIa cross-linking
The fibrinogen isolatedf rom subject plasma, containedv ery little if anyFXIII ( Fig.4;lanes 7and 8) , indicating that the foregoing experiments were performed with non-crosslinked fibrin clots. Whenclots were crosslinked by the addition of FXIII, no difference in α-chain disappearance rate could be observedbetween the non-diabetic,u ncontrolled diabetic, and controlled diabetic subjects, as therea ppearedt ob en os ignificant difference in the percentage α-chaindensity at anyofthe threetime points (10 min: 19.7±6.0; 22.6 ±1.7; 21.6 ±3.9; 45 min: 6.6 ± 4.6; 9.7 ±3.3; 12.4 ±3.6; and 90 min: 2.6 ±3.6; 3.5 ±2.0; 6.2 ± 4.1 of incubation with FXIIIa) using SDS-PAGE. Differencesin γ-chaindisappearance could not be measured as γ-chaincrosslinkingwas alreadycompleted in all the subjects by 10 min (Fig.  4; lanes1and 2) .
Discussion
This is the first intervention trialinvestigating the effect of glycaemic control on fibrin network structures of type 2d iabetic subjectsu sing isolatedfibrinogen. Then etwork structures obtainedf rom plasmac lots from this same study, were reported previously (14) . Using the plasma model, no difference in porosity,compaction and kinetics of clot formation betweenthe diabetic and non-diabetic subjects at baseline waso bserved. Nor were anychangesobservedduring the intervention in these variablesinthe diabetic group, despite asignificant reduction in the leveloffibrinogenglycation (14) . This observedlack of effect could in part be explained by the fibrinogen concentration of the subjects. Boththe non-diabetic and diabetic subjects had similar and raised fibrinogen concentrations and the resultsshowedthat the fibrin network characteristics measuredwere related to fibrinogen concentration and not to anyo ft he glucose control markers. Fibrinogen concentration is acknowledgedasone of the most important kinetic factorsinvolved in the formation of the fibrin network and its final structure (28) . As describedi nt his study,ap urified fibrinogen model enables us to determine the effectsoffibrinogenglycation on fibrin network structureindependent of other plasma components. In contrast to that reported using plasma, therewas asignificant increasei np ermeability with achievement of glycaemic control and consequent decreaseinthe leveloffibrinogenglycation in the diabetic subjects. Asimilarincrease in permeability wasobservedi nt ype 1d iabetic subjectso nc ontinuous subcutaneous insulin infusion, although it wasnot related to glycaemic control (16).The diabetic subjects also displayed asignificantly faster rate of lateralfibrin aggregation (slope) and aslowerl ysis rate than the non-diabetic subjects, whichd ecreased and increased, respectively,with glycaemic control and reduced levels of fibrinogen glycation. These changes in slope and lysis rate, although small in comparison to the differences between diabetic and nondiabetic subjects, were consistently seen in allofthe selecteddiabetic patients in the sub-sample. Permeability,s lope and lysis rate correlated significantlywith markers of glycaemic control suchasHbA1c,fasting venous glucose and fibrinogen glycation, confirming the observedc hangesw ere related to changes observed in glucose concentrations.This mayexplain whythe decrease in the rate of lateral association reached significance in the subgroup, butnot in the total diabetic group, as the decrease in fibrinogen glycation in the total group wasonaverage smaller thanthat of the subgroup and maytherefore have diluted the decrease in the slope in the total group.
The increase in permeability upon achievement of glycaemic control reflectsanincreased pore size of the fibrin network and maybearesult of altered clotformation kinetics. The decrease in the slope of the turbiditycurve upon glycaemic control indicates that the kinetics of polymerization, specificallyl ateral aggregation, are modifiedasaresultofthe decrease in glycation, resulting in an increased pore size.The rate of lateral aggregation maybeinfluencedbyfactorssuch as modulation of binding affinity or possible conformational and chargechanges (29) , as has beendocumented for calcium (30) and chloride (31, 32) . Similar changes maybeinducedbythe presenceofglucose on the fibrinogen molecule.D espite the increased permeability observed, there was, however, no significant difference in medianfiberdiameter between the uncontrolleda nd controlled diabetic subjects. This mayb ee xplained by the fact thatt he permeability measurement is afunctional measurement whichisalso amore sensitive method thanelectronmicroscopyand is therefore able to detect smaller differences. In addition, the diabetic condition is complex, with variousfactorsh aving varying degrees of influence on the different aspects of fibrin network structure, whichm ay lead to the seeminglyi nconsistent results. Similar discrepancies were observedb yt he group of Dunn et al. (10) whofound clots from diabetic patients to be more dense and less porous than that of control patients, buthaving increased,rather thandecreased,fiberdiameters.
Although this studys howedn oc hange in the mechanical propertieso ft he clots after achievement of glycaemic control, the diabetic subjectsincomparison with non-diabetic subjects, had clots with alower proportion of the inelastic to elastic componentofdeformation both before and after achievement of glycaemic control. Thesemechanical propertiesoffibrin are functionallye ssential. Its structure hast ob eb es trong enought o withstand thepressure of arterial blood flowand these properties will determine whether athrombus will deformreversibly or irreversibly, rupture or embolize,u nder the pressure of flowing blood (33) .
Diabetes is consideredah ypercoagulable state due to, amongst other reasons, arelativelyinhibited fibrinolytic system (34) .E x-vivo lysis rates of type 2d iabetic subjectsh aveb een shown to be decreased when compared to non-diabetic subjects (15),using tPAasalytic agent. Our resultsare in agreement with these findings. We demonstrated for the first time thatlysis rate increases in type 2diabetic subjectswhen glycaemic control is achieved. While lysis rate, permeability and the rate of lateral aggregation correlated significantlyw ith markers of glycaemic control, glycation of fibrinogen maynot be the onlycausefor the observedc hanges. In addition to hyperglycaemia, poor glycaemic control is also associated with oxidative and carbonyl stress (35) ,which in turnhavebeen shown to alterthe structure of the fibrinogen molecule (36) .Itisimportant to note thatthe differencesi nl ysis rates observedi nt his study were obtained usingnon-crosslinked clots and the differencesinlysis rates can therefore not be attributed to possible differencesinFXIIIa-induced crosslinking. Dunn et al. (15) demonstrated that binding of bothtPA and plasminogentofibrin is impaired in diabetic subjectsand that thereisacorresponding decreaseinplasmin generation on the clot surface, whichi np arte xplains the reduced lysis rates of diabetic subjects. These changes in enzyme kinetics maybedirectly related to the binding of additionalmolecules to fibrin as aresultofhyperglycaemia or indirectlythrough the resultant altered fibrin network architecture (e.g. increased pore size and higher proportion of thicker fibers), whichh as been shown to be am odulator of fibrinolysis speed ( 3, 4) , or most likelyacombination of both.
The effect of fibrinogen glycation on FXIIIa-inducedcrosslinkingisnot clear.Nodifferences in either γ-orα-chaincrosslinkingw ere observed when clotsm ade from in vitro glycated and normal fibrinogen were compared (6) (7) (8) . When diabetic and non-diabetic subjectsw ere compared, α-chainc rosslinkingo f diabetic subjects were previouslyf ound to be either decreased (12) or increased (10) ,and in our study,comparable to non-diabetic subjects. These discrepancies maybeattributedtothe different sample populations studied,differences in studydesigns and therefore differentl evelso ff ibrinogeng lycation, or glycation of FXIII itself,ordifferences in analytical procedures.In our study therew as additionallyn od iscernable differences in FXIIIa-induced crosslinkingo bservedb etween uncontrolled and controlleddiabetic subjects.
In conclusion, usingap urified model, we determinedt hat achievement of glycaemic control alters the kineticso ff ibrin polymerization,s pecificallyl ateral aggregation and improves permeability and lysis rate whichmay aidinthe alleviation of the hypercoagulable state of diabetic subjects. Despitethe fact that these variablesw ere improved in alls ubjects, the changes observedinlateral aggregation and lysis rate were relativelysmall compared to the initialdifferences observedbetween the uncontrolleddiabetic and non-diabetic subjects. This observation confirmsthat diabetes is acomplexcondition with manymetabolic derangements having modulating effectso nf ibrin network structure, suchasfibrinogenconcentration, as wasdemonstrated in the plasma model (14) . Therefore, the effect of individual contributing factorso nf ibrin networkc haracteristics and the relative magnitude of the consequences amongstthe manyother causal factors in vivo, where whole blood clots areformed in the presenceofplatelets and blood flow, remaintobeelucidated.
